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Antidiabetic Effect of Salvianolic Acid A on Diabetic Animal Models via AMPK Activation and Mitochondrial Regulation

Introduction
Diabetes mellitus (DM) and its complications are running rampantly in the world, which is associated with increased morbidity and mortality. As hyperglycemia is a fundamental abnormality contributing to macrovascular and microvascular complications, glucose-lowering strategy is very important in the treatment of type 2 diabetes to reduce the risk for diabetes complications [1, 2] . Since oral antidiabetic agents were available in more and more emerging drug safety issues have gained extensive concerns [3] . The use of metformin is contraindicated in patients with renal dysfunction [4] . In addition, food and drug administration (FDA) issued a new warning about the side effects of thiazolidinediones (TZDs), such as weight gain, edema, heart and liver failure. Therefore, development of mitochondrial function and AMP-activated protein kinase (AMPK) are known to be closely involved in glucose metabolism, which have been regarded as the potential therapeutic targets for diabetes and diabetes complications. diseases in developing countries [5, 6] . Plants have the ability to synthesize a wide variety of chemical compounds, which give a great opportunity for the discovery of antidiabetic agents. Salvianolic acid is a polyphenolic compound isolated from the root of Salvia Miltiorrhiza Bunge, which is a traditional Chinese medicine and widely used in the Asian countries for the treatment of cardiovascular and cerebrovascular diseases with well-(3,4-dihydroxyphenyl) ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid) has been reported to have extensive pharmacological effects including antioxidant, anti-platelet aggregation, anti-cerebral and myocardial ischemia [8] [9] [10] [11] [12] . Salvianolic acid B, as one of salvianolic acid, was found to protect against high-fat diet-induced obesity recently [13] . In our previous studies, we have demonstrated that SalA ameliorated diabetes complications, such as vascular disease and peripheral neuropathy [14] [15] [16] .
as well as reduces food and water intakes. Further studies demonstrated that SalA regulates glucose metabolism by increasing ATP production, decreasing mitochondrial membrane potential (MMP) and improving mitochondrial function via Ca 2+ /calmodulin-dependent kinase (PI3K)/Akt signaling pathway. All these results indicated that SalA might be a novel and promising drug candidate for diabetes treatment.
Type 2 diabetic Rats and treatments
standard diet (41.47% carbohydrate, 14.42% fat, 21.06% protein), while rats in diabetic group were fed with high-fat and high-sucrose diet (standard rat diet supplemented with 10% sucrose, 10% lard, 2% cholesterol, and 0.2% cholic acid) for 4 weeks, and then injected intraperitoneally with streptozotocin (STZ, were considered as diabetic rats. The diabetic rats were randomly divided into 4 groups: untreated diabetic group (DM group), metformin-treated diabetic group (Metformin 150 mg/kg) and SalA-treated diabetic group (SalA 1 and 3 mg/kg). All diabetic rats were fed with a high-fat diet (standard rat diet supplemented with 10% lard, 2% cholesterol, 0.2% cholic acid), while NC rats were fed with a standard diet for 4 weeks.
Measurements of blood glucose, glycosylated hemoglobin and oral glucose tolerance test
(Beijing Biosino Co, China). To determine FBG, animals were fasted for 4 h. Fed blood glucose samples were collected without fasting and free to feed. Oral glucose tolerance test (OGTT) was performed after the animals were fasted for 4 h followed by glucose solution (2.0 g/kg) by oral gavage. The blood samples were collected at 0, 30, 60, 120 min after glucose loading.
Cell Culture
with 10% FBS at 37 °C, 5% CO 2 2 . . After treatment for 24h, the supernatant was taken for glucose assay.
Glucose consumption and glucose uptake
The glucose uptake was performed with the radioactive substances [ TM reagent was added and mixed thoroughly. The luminescence was recorded by Spectra Max .
Measurement of mitochondrial function
Isolation of mitochondria. The isolation of mitochondria was performed as previously described [22] .
The tissue homogenates (10%, w/v) were generated in glass homogenizer. After removing cell debris by centrifugation at 1000 g for 10 min, the supernatant was subjected to further centrifugation at 10,000 g for
Measurement of mitochondrial respiratory activity
Oxygen consumption was measured by Clark type oxygen electrodes (Strathkelvin Instruments, British) at 25 °C. Mitochondrial respiration was detected by adding 1 mg/ml hepatic or skeletal muscle were incubated with different concentrations of SalA (10 -10 -6 M) for 24 h, MTT (0.5 mg/ml) was added into cells and incubated at 37 °C for 4 h. Then the supernatant was discarded and DMSO was added. The OD value at 570 nm was recorded by Spectra Max . 
Western blotting
Results
Metabolic consequences of SalA in diabetic animal models Polydipsia, polyphagia, polyuria are characteristic of diabetes, which can be improved by hypoglycemic agent treatment. Improvement of blood glucose is usually concomitant with the reduction of food and water intake. In type 1 diabetic mice, 24-h food and water intake were reduced after 7-day SalA treatment , and markedly reduced after 14-day treatment, stronger than metformin (Fig. 1A, 1B ). As shown in Fig. 1C , 14-days treatment of SalA (0.4, 1.3 mg/kg) exhibited mild hypoglycemic effect on FBG with about 16% decrease compared fed blood glucose in a dose-dependent manner, with a little stronger effect than metformin (Fig. 1D) . In OGTT, compared with DM group, SalA lowered the blood glucose after glucose fed blood glucose in dose-dependent manner, similar to metformin (Fig. 2B, 2C ). Glycosylated months. Compared with DM group, SalA markedly reduced the glycosylated hemoglobin, 
SalA increased glucose consumption and enhanced glucose uptake
Since SalA displayed the antidiabetic effect in vivo, we then investigated the glucose metabolic activity of SalA in vitro to unveil the mechanisms. To this end, we examined the treated by SalA. 10 -6 M SalA had the strongest effect, similar to 10 -7 M insulin (36% increase, Fig. 3C ). It suggested that SalA can increase glucose consumption and enhance glucose uptake in vitro. 
Cellular Physiology and Biochemistry
SalA did not stimulate insulin release in MIN6 cells
To clarify whether SalA lower the blood glucose through stimulating insulin release like insulin, MIN6 cells were treated with SalA at different concentrations for 24 h. Both of (Fig. 4A, 4B ), which suggested that SalA had no insulin secretagogue effect.
Effects of SalA on mitochondrial function
SalA increased ATP production in mitochondria. ATP production is the main activity of mitochondria. To explore whether SalA targets mitochondrial function, we investigated the effects of SalA on ATP production in both cultured cells and isolated mitochondria. After dose-dependent increase from 10 min to 12 h with the strongest effect at 10 -7 M and 10 -6 M (Fig. 5A , 5B). In isolated mitochondria, SalA increased ATP production dose-dependently in (Fig. 5C, 5D ). Altogether, SalA increased ATP production in mitochondria.
SalA decreased mitochondrial membrane potential. Monitoring mitochondrial membrane potential is used to assess mitochondrial function. A lower membrane potential can prevent free radical production. So, we investigated whether SalA works on mitochondrial membrane potential. Interestingly, our results showed that 30-min treatment of SalA dose-dependently membrane potential in hepatocytes (Fig. 6A, 6B) . In isolated hepatic and skeletal muscle mitochondria, we also found that mitochondrial membrane potential was decreased after 10-min treatment of SalA (Fig. 6C, 6D) . Collectively, SalA decreased mitochondrial membrane potential in hepatic and skeletal muscle mitochondria.
SalA improved mitochondrial respiratory functions.
have demonstrated that SalA improved the mitochondrial function in high-fat diet-fed AMPK is a metabolic master switch regulating mitochondria, glucose uptake and fatty acid oxidation [29] . To explore if AMPK is involved in the antidiabetic mechanisms of SalA, we detected results showed that AMPK was phosphorylated in a dose-and time-dependent manner under SalA stimulation (Fig. 7A-F) .
SalA did not activate phosphorylation of Akt. To test whether SalA modulates glucose metabolism via PI3K/Akt pathway known to play a major regulatory role in insulin pathway, we detected the Akt expression under SalA treatment. Our results showed that SalA did not exhibited antidiabetic effect not through PI3K/Akt signaling pathway, consistent with the absent insulin-secretagogue effect of SalA. 
Discussion
In this report, we have demonstrated that SalA, a small-molecular-weight natural product from Salvia Miltiorrhiza Bunge, exhibits antidiabetic effect in both in vivo and in vitro. SalA lowered fasting and fed blood glucose in both type 1 diabetic mouse and type 2 diabetic rat models, as well as increased glucose consumption in hepatocytes and enhanced pathway.
The majority of ATP is generated by proton gradient in the mitochondria through oxidative phosphorylation during glucose metabolism. ATP is requisite to maintain the cellular processes and adequate ATP supplements by energy metabolisms are crucial for the treatment and prevention of many diseases [30] . It is well known that type 2 diabetes is not . Our previous studies demonstrated that SalA promoted ATP production in myocardial, endothelial and smooth muscle cell (data not shown). In the current study, we found that SalA increased ATP production in both hepatic respiratory function of liver and skeletal muscle. Taken together, these data indicated that SalA exhibited the antidiabetic effect through targeting mitochondria.
to induce mitochondrial superoxide production, not only contributing to the development of complications, but also being involved during post-hyperglycemia periods of normal study, SalA promoted the intracellular ATP production, while decreased mitochondrial STZ-induced type 2 diabetic rats [3, 16, 28]. More interestingly, the effect of SalA is different from the common antidiabetic agents, as both metformin and TZDs inhibit complex I activity membrane potential might be an important target for development of antidiabetic agents [38] . In our study, SalA decreased mitochondrial membrane potential level and increased ATP production. These unique functions of SalA make it appealing for diabetes treatment. AMPK, a serine/threonine protein kinase, acts as a metabolic master switch regulating cellular metabolism and energy balance [39] . Abnormal AMPK activity is closely associated with diabetes. Therefore, AMPK has been recognized as a promising therapeutic target for type 2 diabetes [38, 40] . Some antidiabetic agents, such as metformin, rosiglitazone, and . So AMPK is involved in ATP production and maintenance of glucose homeostasis. Thus, SalA activates phosphorylation of AMPK, which triggers intracellular metabolic changes, including increasing glucose uptake in skeletal muscle and decreasing glucose production in liver, and eventually leads to glucose-lowering.
intracellular Ca 2+ concentrations, independent of any changes in cellular AMP/ATP ratio Increasing glucose consumption and glucose uptake in periphery tissues (liver and skeletal muscle) contributes to lowering postprandial glucose. It is well known that in addition to fasting hyperglycemia, postprandial hyperglycemia is also one of the earliest abnormalities of glucose homeostasis associated with type 2 diabetes and is markedly exaggerated with fasting hyperglycemia [48] . SalA lowered fasting blood glucose mildly in safety makes SalA attractive in the development of antidiabetic drug.
Taken together, SalA exhibits the antidiabetic effect through improving mitochondrial activities of decreasing mitochondrial membrane potential and increasing ATP production serve as a novel and potential therapeutic option for diabetes treatment. 
